Pharmaceutical company Chrysalis BioTherapeutics Inc reported on Wednesday the receipt of the Orphan Drug Designation (ODD) for its lead compound TP508 (rusalatide acetate) for the treatment of acute radiation syndrome (ARS), from the US Food and Drug Administration (FDA) Office of Orphan Product Development and the European Medicines Agency (EMA).
Following exposure to high levels of nuclear radiation, individuals develop ARS or radiation sickness affecting multiple organ systems and often leading to death within days, weeks, or months of exposure.
TP508 is a regenerative peptide drug representing a natural part of human thrombin that is released upon tissue injury to initiate healing.
The compound has demonstrated safety and potential efficacy in non-clinical and in human clinical tissue repair trials, Chrysalis BioTherapeutics said.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML